Tiagabine hydrochloride hydrate

Tiagabine (2-5 mg/kg; i.p., daily administration, lifelong treatment) hydrochloride hydrate extends the survival of male N171-82Q transgenic Huntington's disease mice (up to 33.4 days at the 5 mg/kg dose), improves their motor function, and alleviates brain atrophy and neurodegeneration^[1].
Tiagabine (5 mg/kg; i.p.; daily; lifelong administration) hydrochloride hydrate extends the survival of male and female R6/2 transgenic Huntington's disease mice (17.8 days of extension at the dose of 5 mg/kg), improves their motor function, and alleviates brain atrophy^[1].
Tiagabine (0.4 mg/kg; i.p.; single administration; 30 min prior to seizure testing) hydrochloride hydrate exerts a protective effect against audiogenic tonic seizures in male DBA/2 mice, with an ED₅₀ of 0.4 mg/kg^[2].
Tiagabine (1.2-1.3 mg/kg; i.p.; single administration; 30 min prior to seizure tests) hydrochloride hydrate exerts a protective effect against PTZ-induced tonic convulsions in male NMRI mice, with an ED₅₀ of 1.2 mg/kg, while providing approximately 50% partial protection against clonic convulsions^[2].
Tiagabine (15-30 mg/kg; p.o.; twice daily; for consecutive 21 days) hydrochloride hydrate induces tolerance to cognitive effects in mice, but does not induce tolerance to its anticonvulsant effects in DMCM-induced epileptic mice^[3].
Tiagabine (9 mg/kg; subcutaneous injection; once daily for 8 consecutive days; single injection 30 min prior to locomotor activity test) hydrochloride hydrate initially reduces short-term spontaneous ethanol intake in ad libitum-fed C57BL/6 mice, but tolerance develops rapidly, resulting in ethanol intake exceeding pre-treatment levels on days 7-8^[5].